Median Technologies

🌟 In Case You Missed It! 🌟 Sébastien Jacques, Head of Imaging Lab at Median Technologies, recently shared invaluable insights on the transformative power of #AI in imaging for #clinicaltrials. In his latest article, he explores 5 groundbreaking ways AI-powered imaging is shaping the future of oncology clinical trials. Whether you're involved in clinical research or just curious about the future of healthcare, this is a must-read! Take just 5 minutes to stay ahead of the curve and see how AI is revolutionizing oncology. Don’t miss out on what’s coming next! 👉 [Read the full article here]:  https://lnkd.in/eS6aZxgq #ImagingLab #OncologyTrials #AIinHealthcare #MedicalImaging

🌟Proud to be part of the #GO2 #LungCancer Summit🌟 This event offers an exciting opportunity to explore the experiences of cancer survivors, the pivotal role of nurse navigators 🏥, and invaluable insights from doctors 👨⚕️👩⚕️. But what about the future? 🤖 Let's talk about #AI and #SaMD!🧠 Antoine Disset, PhD and I will be available at Booth #19 to discuss how AI can revolutionize the lung cancer landscape by enhancing early diagnosis and improving patient outcomes. 🩺✨ We’re looking forward to sharing more with you! 💬 #CancerInnovation #EarlyDiagnosis #HealthTech #Median #eyonis

🌸 October is Breast Cancer Awareness Month, a global initiative focused on raising awareness and promoting early detection—two key factors in the fight against breast cancer. 📊 According to the WHO, 1 in 12 women will be diagnosed with breast cancer in their lifetime. Let’s dive into how Artificial Intelligence (AI) and medical imaging are transforming the early detection of breast cancer. Click here for more information about breast cancer: https://lnkd.in/deUKJGp Click here to know more about Pink October: https://lnkd.in/eRq9PX2 #BreastCancerAwareness #PinkOctober

📢 Check out our latest article featured in the ESR Weekly Highlights Newsletter! "RECIST 1.1 Assessments Variability: A Systematic Pictorial Review of Blinded Double Reads" by Antoine IANNESSI, hubert beaumont, Christine Ojango, Anne-Sophie Bertrand & Yan Liu, published in Insights into Imaging. This comprehensive review explores the root causes of variability in RECIST 1.1 evaluations and offers proactive solutions for radiologists. From improving radiologist expertise to enhancing image quality and reducing lesion selection bias, the article emphasizes the importance of standardized protocols to minimize discordance and improve clinical trial outcomes. #Oncology #RECIST #ClinicalTrials #MedicalImaging #BICR #HealthcareInnovation #ImagingInsights

The Median #eyonis™ team is excited to sponsor the upcoming Center of Excellence Summit & Lung Cancer Navigator Workshop in Chicago, hosted by #GO2! We are honored to participate in this important event, dedicated to patient care, supporting caregivers, and sharing the latest advancements in #LungCancerScreening & treatment. If you're interested in learning how the eyonis™ team can make a difference, we invite you to visit us at booth #19. We’ll be delighted to discuss how our #AI/ML-powered Software as a Medical Device , eyonis™ LCS, has the potential to enhance early diagnosis and improve patients' lives. #eyonis #Screening #SaMD 

The significance of World Lung Day lies in its effort to tackle the rising rates of lung diseases, with lung cancer being one of the most critical threats. This day also aims to inspire policymakers and the public to take decisive action for global lung health (1). At #Median, we're currently investing in #eyonis™ LCS , our AI/ML tech-based CADe/CADx #SaMD, to support early-stage #lungcancer detection, empowering radiologists and pulmonologists to drive #lungcancerscreening and clinical management.

📢 Meet Median at Outsourcing in Clinical Trials Southern California – happening today and tomorrow!   Christian Teague, our U.S. Business Development Director , will be there to discuss how you can shorten timelines and ensure operational excellence by choosing Median as your global imaging partner for your Phase I-III oncology trials. Plus, learn more about how our AI-powered imaging services are driving innovation and delivering actionable insights to accelerate cancer treatment development.   Connect with Christian on LinkedIn to learn how Median can support your oncology programs! #OCTSouthernCalifornia #MeetMedian #OncologyTrials #AI #MedicalImaging #ClinicalTrials #Pharma

Estimates show cancer will be the leading cause of death in the coming years, rising to 21.6 million cases worldwide. Hence, #WorldCancerResearch Day marks a chance to boost research efforts to slow disease progression, improving patient survival rates and quality of life (1). That's why at #Median, we are investing in the development of #eyonis™, our suite of AI/ML technology-based Software as a Medical Device (#SaMD). Designed to support radiologists and healthcare professionals in the interpretation of #medicalimages, with a focus on the #earlydiagnosis and treatment of #lungcancer. Ref: (1) World Cancer Research Day |.(n.d.). https://lnkd.in/d3sCkBs

At Median, we believe that excellence starts with a proactive approach. Our Clinical Trial Imaging Team has consistently gone above and beyond, ensuring seamless execution and delivering top-tier results for our clients. Their dedication to anticipating needs and providing innovative solutions makes a significant impact on every project. Thank you to the entire team for your commitment to excellence! Learn more about our imaging services for oncology trials here: https://lnkd.in/dgNWW3gj #ClinicalTrials #MedicalImaging #Teamwork #Proactivity #HealthcareInnovation

#AI can help enhance #screeningprograms through the collection and analysis of a huge amount of imaging and #clinicaldata. AI also allows risk stratification and subsequent screening personalization. A computer-aided detection (#CAD) system assists in lung nodule detection, reducing imaging time interpretation [1]. At #Median we are developing #eyonis™, our #AI/ #ML tech-based Software as Medical Device (#SaMD), that will not only detect nodules at early stage with its #CADe, but also characterize them with its #CADx part. This comprehensive functionality makes our eyonis™ product suite a robust support system for radiologists and clinicians in the implementation of effective lung cancer screening programs Reference: [1] Cellina M. et al.,(2023). Artificial intelligence in lung cancer screening: The future is now. Cancers, 15(17), 4344. https://lnkd.in/gcHZ2Rea